# Tofacitinib for Immune Skin Conditions in Down Syndrome

> **NCT04246372** · PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 47 (actual)

## Conditions studied

- Down Syndrome
- Alopecia Areata
- Atopic Dermatitis / Eczema
- Hidradenitis Suppurativa
- Vitiligo
- Psoriasis

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT04246372
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04246372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04246372, "Tofacitinib for Immune Skin Conditions in Down Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04246372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*